Also, these investigators hypothesized that specific mutations that may impact outcome differ by racial and ethnic group based on their data from the Cancer and Leukemia Group B/Alliance trials where they observed that OS was not improved in favorable-risk NPM1-mutated/FLT3-IHDlow/no AML in young Black patients compared with White patients, albeit based on small numbers of cases.16 Here, FLT3 is linked to cancer.